News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
(USGovernment-News.Com, March 15, 2013 ) Columbus, OH -- The Mirena IUD Lawsuit Information Center has learned that on March 21 there will be arguments over the proposed transfer of eight Mirena IUD lawsuits to a federal district court in Ohio for consolidation into multidistrict litigation.
Arguments over the proposed consolidation of at least eight personal injury claims against Bayer into MDL No. 2434 will take place on March 21 in San Diego, Calif., according to page 7 of a Notice of Hearing Session by the United States Judicial Panel on Multidistrict Litigation.
The pretrial proceedings of the cases in MDL No. 2434 will be overseen by a judge in the U.S. District Court for the Northern District of Ohio, according to the notice. The cases being considered for consolidation are currently pending in federal district courts in Arkansas, California, Georgia, Kentucky, Ohio, Carolina and Texas.
The Mirena IUD, which is manufactured by Bayer AG and was approved by the FDA in 2000, is a “hormonal IUD,” meaning it releases roughly 20 mcg per day of levonorgestrel (the hormone progestogen) while it is in place. The progestogen further reduces the likelihood of pregnancy above the benefits of non-hormonal IUDs, and it can even reduce heavy menstrual bleeding, a condition for which the FDA gave Bayer permission to sell the Mirena IUD in 2009. About two million women in the United States now use Mirena IUDs, according to Bloomberg.
The Mirena carries with it some potentially serious side effects, including device perforation (puncture of the uterine wall), migration (the shifting of the device to outside of the woman’s uterus), and embedment (the device becomes stuck in the uterine wall). The product information for the Mirena IUD also indicates that, if a woman becomes pregnant when using the device, her offspring might be at risk of sustaining Mirena IUD birth defects.
In 2009, Bayer encountered pushback from the FDA for its Mirena IUD marketing strategy, which included advertising the device as appropriate for “busy moms,” and using a social networking web site called “Mom Central” to organize Mirena IUD parties either at people’s homes or at restaurants. At the parties, a representative from Mom Central and a nurse practitioner would together explain the benefits of using a Mirena IUD, using scripted language that suggested a Mirena IUD would improve a woman’s intimacy and romance with their partners, as well as make them “look and feel great.”
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:
